DEVELOPMENT OF NOVEL ANALYTICAL AND DIAGNOSTIC TOOLS USING NANOTECHNOLOGY AND MICROFLUIDICS
With
Dr Alain Wuethrich
NHMRC Emerging Leader Fellow
Australian Institute for Bioengineering and Nanotechnology,
The University of Queensland
Brisbane, Australia
RESEARCHER PROFILE
Filmed in Brisbane | June 2025
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
A feature of his work has been the ability to translate discoveries at the nanoscale into highly innovative diagnostics that enable the precise study of biomolecular aberrations in cancer, infectious diseases, and human immune system.
His particular research expertise lies in:
– Liquid biopsy
– Electrohydrodynamics
– Surface-enhanced Raman spectroscopy
– Nanotechnology
– Diagnostics
Dr Wuethrich held positions in international pharmaceutical companies and became lead inventor on a European patent.
He has actively engaged with national and international companies to translate diagnostic nanotechnologies. His network of national and international collaborators include the Princess Alexandra Hospital, UQ Diamantina Institute, UQ Centre for Clinical Research, QIMR Berghofer, and the Dana-Farber Cancer Institute.
Since 2017 he has provided continuous research mentoring to the group and has supervised more than 30 postgraduate and graduate students in nanotechnological strategies to detect cancer and other diseases.
In May 2024 Dr Wuethrich won a $1.6 million NHMRC Emerging Leader 2 grant to develop digital nanotechnology capable of detecting trace immune dysregulation from a pin-prick of blood.
He says understanding immune dysregulation is crucial for addressing emerging diseases like Long Covid and for future-proofing immune-modulating mRNA vaccines.
“The technology we have in mind will be 1000 times more sensitive than conventional methods,” Dr Wuethrich said.
“Hopefully, this will lead to a better understanding, diagnosis, and treatment of diseases like long COVID, and the development of personalised vaccines with greatly reduced side effects.”
Dr Wuethrich is one of two Investigator Grant winners currently working with Professor Matt Trau.
Source: Supplied
-
Dietary Interventions Influencing Neurological Outcomes
With over a decade of experience as a dietitian and nutritionist, Carolina Blagojevic Castro specialises in providing personalised dietary guidance and customised meal planning tailored to meet each client’s unique health needs. She is known for her engaging and educational presentations on topics related to health and nutrition, sharing practical, evidence-based insights with both community groups and professional audiences.
-
Biostatistics in Clinical Trials
As a biostatistician working in research and clinical settings, Kate Francis plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
-
Clinical Research in Emergency Medicine
Professor Daniel Fatovich is a senior emergency physician and clinical researcher at Royal Perth Hospital Emergency Department (ED), with over 30 years’ experience in the design and conduct of clinical research in Emergency Medicine. He is also Head of the Centre for Clinical Research in Emergency Medicine (CCREM) within the Harry Perkins Institute of Medical Research.
